Barron's Article Makes Positive Comments on Onyx Pharmaceuticals (ONXX)
More News related to BAY
- Bayer USA Foundation Announces $100,000 Donation to The Wellness Community
- Bayswater Expands Drilling Program at Elkhorn Project, Wyoming
- Bayswater Seeks Approval to Amend the Terms of Its Outstanding Warrants
- Bayswater's Drilling Further Expands Elkhorn Uranium Project, Wyoming
- Drilling Continues to Expand Anna Lake Uranium Deposit, Central Mineral Belt Uranium Project, Labrador
More News related to ONXX
- Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
- Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
- Onyx Pharma (ONXX) Active on Takeover Buzz
- Onyx Pharma (ONXX) volume & volatility Jump on sharp rally
- Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
More News related to Analyst Comments
- Canada's Government Supports Community Organizations Targeted by Hate Crime
- Ladish Completes Merger with Chen-Tech Industries
- Rite Aid Continues to Assist with Hurricane Relief Efforts
- Indulgent Wine Country Experiences -- Surprisingly Affordable, Close to Home & Designed Just for You
- Government of Canada Invests in Healthy Food Products for Children
Barron's article makes positive comments on Onyx Pharmaceuticals (Nasdaq: ONXX), saying current valuation looks cheap, and highlights the company's Nexavar compound, which was developed through a 50-50 partnership with a unit of Bayer AG (NYSE: BAY).
The article does point out that the share price has been very volatile in the past, but feels the company's positive balance sheet, no debt and a growing partnership with Bayer might help the company/shares be less prone to erratic behavior. (Shares have fluctuated between $3 and $60 over the past 5-6 years)
Barron's also points out that Nexavar's potential is huge and that several positive studies have concluded and the drug may be helpful in even more than two types of cancers.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer.
Related Categories
Analyst CommentsStocks Mentioned
-0.41Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
